PURPOSE: Our aim was to evaluate the literature for the prevalence of and interventions for oral viral infections and, based on scientific evidence, point to effective treatment protocols. Quality of life (QOL) and economic impact were assessed if available in the articles reviewed. METHODS: Our search of the English literature focused on oral viral infections in cancer patients within the timeframe of 1989-2007. Review methods were standardized. Cohort studies were used to determine the weighted prevalence of oral viral infection in cancer patients. The quality of selected articles were assessed and scored with respect to sources of bias, representativeness, scale validity, and sample size. Interventional studies were utilized to determine management guidelines. Literature search included measures of QOL and economic variables. RESULTS: Prevalence of oral herpes simplex virus (HSV) infection in neutropenic patients was higher than in patients treated with radiotherapy for head and neck cancer (49.8% vs. 0%, respectively). In patients treated with radiochemotherapy for head and neck cancer, the prevalence of oral HSV infection increases up to 43.2% (CI, 0-100%). Prevalence of HSV infection was higher when oral ulcers existed. Information about other oral viral infections is sparse. There was a significant benefit of using acyclovir to prevent HSV oral infection (at 800 mg/day). Various dosing protocols of valacyclovir achieved prevention of HSV reactivation (500 or 1,000 mg/day). The prevalence of HSV reactivation was similar for acyclovir and valacyclovir. No information about impact on QOL and economic burden was available. CONCLUSIONS: Acyclovir and valacyclovir are equally effective in preventing oral HSV infection. Neutropenic patients, who were primarily treated for hematological malignancies in the studies reviewed, are at a greater risk for viral infection.
PURPOSE: Our aim was to evaluate the literature for the prevalence of and interventions for oral viral infections and, based on scientific evidence, point to effective treatment protocols. Quality of life (QOL) and economic impact were assessed if available in the articles reviewed. METHODS: Our search of the English literature focused on oral viral infections in cancerpatients within the timeframe of 1989-2007. Review methods were standardized. Cohort studies were used to determine the weighted prevalence of oral viral infection in cancerpatients. The quality of selected articles were assessed and scored with respect to sources of bias, representativeness, scale validity, and sample size. Interventional studies were utilized to determine management guidelines. Literature search included measures of QOL and economic variables. RESULTS: Prevalence of oral herpes simplex virus (HSV) infection in neutropenicpatients was higher than in patients treated with radiotherapy for head and neck cancer (49.8% vs. 0%, respectively). In patients treated with radiochemotherapy for head and neck cancer, the prevalence of oral HSV infection increases up to 43.2% (CI, 0-100%). Prevalence of HSV infection was higher when oral ulcers existed. Information about other oral viral infections is sparse. There was a significant benefit of using acyclovir to prevent HSV oral infection (at 800 mg/day). Various dosing protocols of valacyclovir achieved prevention of HSV reactivation (500 or 1,000 mg/day). The prevalence of HSV reactivation was similar for acyclovir and valacyclovir. No information about impact on QOL and economic burden was available. CONCLUSIONS:Acyclovir and valacyclovir are equally effective in preventing oral HSV infection. Neutropenicpatients, who were primarily treated for hematological malignancies in the studies reviewed, are at a greater risk for viral infection.
Authors: K M Sullivan; C A Dykewicz; D L Longworth; M Boeckh; L R Baden; R H Rubin; K A Sepkowitz Journal: Hematology Am Soc Hematol Educ Program Date: 2001
Authors: V Ramírez-Amador; L Esquivel-Pedraza; A Mohar; E Reynoso-Gómez; P Volkow-Fernández; J Guarner; G Sánchez-Mejorada Journal: Eur J Cancer B Oral Oncol Date: 1996-09
Authors: L R Stanberry; S A Floyd-Reising; B L Connelly; S J Alter; M J Gilchrist; C Rubio; M G Myers Journal: Clin Infect Dis Date: 1994-03 Impact factor: 9.079
Authors: Sharon Elad; Vinisha Ranna; Anura Ariyawardana; Maria Elvira Pizzigatti Correa; Vanessa Tilly; Raj G Nair; Tanya Rouleau; Richard M Logan; Andres Pinto; Veronica Charette; Debbie P Saunders; Siri Beier Jensen Journal: Support Care Cancer Date: 2016-11-16 Impact factor: 3.603
Authors: Regina Maria Holanda de Mendonça; Marcela de Araújo; Carlos Emilio Levy; Joseane Morari; Rosângela A Silva; José Andres Yunes; Silvia Regina Brandalise Journal: Support Care Cancer Date: 2011-05-20 Impact factor: 3.603
Authors: Andreza Veruska Lira Correia; Maria Rosângela Cunha Duarte Coêlho; Georgea Gertrudes de Oliveira Mendes Cahú; Jéfferson Luis de Almeida Silva; Catarina da Mota Vasconcelos Brasil; Jurema Freire Lisboa de Castro Journal: Support Care Cancer Date: 2014-12-30 Impact factor: 3.603
Authors: Ritu Aggarwal; Deepak Bansal; Jasmine Naru; Manila Salaria; Anita Rana; Ranjana W Minz; Amita Trehan; R K Marwaha Journal: Support Care Cancer Date: 2014-02-14 Impact factor: 3.603
Authors: Sharon Elad; Judith E Raber-Durlacher; Michael T Brennan; Deborah P Saunders; Arno P Mank; Yehuda Zadik; Barry Quinn; Joel B Epstein; Nicole M A Blijlevens; Tuomas Waltimo; Jakob R Passweg; M Elvira P Correa; Göran Dahllöf; Karin U E Garming-Legert; Richard M Logan; Carin M J Potting; Michael Y Shapira; Yoshihiko Soga; Jacqui Stringer; Monique A Stokman; Samuel Vokurka; Elisabeth Wallhult; Noam Yarom; Siri Beier Jensen Journal: Support Care Cancer Date: 2014-09-05 Impact factor: 3.603
Authors: T M Haverman; J E Raber-Durlacher; W M H Rademacher; S Vokurka; J B Epstein; C Huisman; M D Hazenberg; J J de Soet; J de Lange; F R Rozema Journal: Mediators Inflamm Date: 2014-04-10 Impact factor: 4.711